Write in a clean editor, then format for Alzheimer's Research & Therapy in one click — DocuGuru applies the official BMC (BioMed Central) template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Alzheimer's Research & Therapy is a peer-reviewed journal published by BMC (BioMed Central), covering Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Functional Brain Connectivity Studies. Over its lifetime it has published 2,351 papers, which have received 104,895 citations.
| Publisher | BMC (BioMed Central) |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Alzheimer's Research & Therapy. 2023;12(3):45–58.
Formats any DOI in Alzheimer's Research & Therapy style. No sign-up. |
| Publishes research in | Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Functional Brain Connectivity Studies Neuroinflammation and Neurodegeneration Mechanisms Intracerebral and Subarachnoid Hemorrhage Research |
| ISSN | 1758-9193 |
| Citation impact (2-yr) | 8.71 |
| h-index | 146 |
| i10-index | 1,611 |
| Article processing charge | $2,931 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | University College London |
| Journal website | link.springer.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
INTRODUCTION: Alzheimer's disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. METHODS: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined…
BACKGROUND: Current projections of the scale of the coming dementia epidemic assume that the age- and sex-specific prevalence of dementia will not vary over time, and that population ageing alone (increasing the number of older people at risk) drives the projected increases. The basis for this assumption is doubtful, and secular trends (that is, gradual…
BACKGROUND: Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomized double-blind clinical trial, utilized a Bayesian design with response-adaptive randomization to assess 3 doses across 2 regimens of lecanemab versus placebo in early Alzheimer's disease, mild cognitive impairment due to…
Due to the progressive aging of the population, Alzheimer's disease (AD) is becoming a healthcare burden of epidemic proportions for which there is currently no cure. Disappointing results from clinical trials performed in mild-moderate AD dementia combined with clear epidemiological evidence on AD risk factors are contributing to the development of primary prevention initiatives. In…
The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer’s Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between…
